Allergy and Immunology · Charlotte, NC
NPI
1295761351
Since 2006
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2600 E 7th St, Unit A
Charlotte, NC, 28204
Phone (704) 372-7900
Groups this clinician bills Medicare through
Medicare paid, 2024
$225K
10,740 services
Medicare patients, 2024
156
Average age 73
Drug cost, 2024
$278K
672 prescriptions
Company payments, 2025
$3,386
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael A Lapuente was code 95004 (test - miscellaneous), 1,684 times for 28 patients. In total Michael A Lapuente billed 10,740 services in 29 codes, and Medicare paid $225K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 1,684 | 28 | $2.52 | $4,240 |
| 95165 Treatment - Miscellaneous | Office | 680 | 27 | $10.29 | $6,998 |
| 95117 Treatment - Miscellaneous | Office | 397 | 21 | $8.30 | $3,296 |
| 95024 Test - Miscellaneous | Office | 270 | 14 | $5.78 | $1,562 |
| 95115 Treatment - Miscellaneous | Office | 266 | 18 | $6.53 | $1,736 |
| 96372 Injection Administration | Office | 223 | 11 | $10.21 | $2,276 |
| 99214 Office E&M - Established | Office | 92 | 72 | $77.64 | $7,143 |
| 99204 Office E&M - New | Office | 36 | 36 | $111.52 | $4,015 |
| 94375 Pulmonary Function Testing | Office | 15 | 13 | $26.93 | $404 |
| 99213 Office E&M - Established | Office | 12 | 12 | $56.77 | $681 |
By year: 2022 $219K for 9,045 services; 2023 $218K for 9,767 services; 2024 $225K for 10,740 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael A Lapuente prescribed most often to Medicare patients was Azelastine Hcl, with 86 prescriptions and refills. In total Michael A Lapuente wrote 672 Medicare prescriptions that cost $278K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azelastine Hcl Generic | 86 | 133 | 35 | $2,320 |
| Breo Ellipta Fluticasone/Vilanterol | 48 | 82 | Under 11 | $31K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 46 | 49 | 19 | $741 |
| Levocetirizine Dihydrochloride Generic | 45 | 97 | 19 | $642 |
| Fluticasone Propionate Generic | 42 | 91 | 18 | $513 |
| Ipratropium Bromide Generic | 37 | 51 | 14 | $875 |
| Prednisone Generic | 29 | 29 | 21 | $61.01 |
| Montelukast Sodium Generic | 27 | 73 | Under 11 | $273 |
| Famotidine Generic | 26 | 54 | Under 11 | $401 |
| Carbinoxamine Maleate Generic | 25 | 40 | Under 11 | $1,316 |
| Epinephrine Generic | 25 | 25 | 23 | $4,517 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 16 | 18 | Under 11 | $1,862 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 14 | 14 | Under 11 | $8,730 |
| Dupixent Pen Dupilumab | 13 | 13 | Under 11 | $50K |
| Dupixent Syringe Dupilumab | 13 | 13 | Under 11 | $49K |
Brand drugs: - claims; generic drugs: 428 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael A Lapuente $3,386 ($3,386 in general payments such as food, travel and fees) from 27 companies. The largest payer was ARS Pharmaceuticals Operations, Inc. with $425.
| Company | Payments | Amount |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. SPRY | 20 | $425 |
| Regeneron Healthcare Solutions, Inc. REGN | 14 | $396 |
| AstraZeneca Pharmaceuticals LP AZN | 18 | $387 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $330 |
| Amgen Inc. AMGN | 7 | $237 |
| GlaxoSmithKline, LLC. GSK | 15 | $220 |
| CSL Behring CSL.AX | 15 | $213 |
| Regeneron Pharmaceuticals, Inc. REGN | 1 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $130 |
| Grifols USA, LLC | 6 | $119 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.